The heterogenous landscape of EGFR Del19 mutation subtype: not all are the same for osimertinib.
作者信息
Duchemann Boris, Fabre Emmanuelle, Remon Jordi
机构信息
Medical and Thoracic Oncology, HUPSSD Avicenne Hospital APHP, Bobigny, France.
INSERM UMR1272, Paris 13, the University Sorbonne Paris Nord, Bobigny, France.
出版信息
Transl Lung Cancer Res. 2024 Apr 29;13(4):952-955. doi: 10.21037/tlcr-24-30. Epub 2024 Apr 24.
Abstract
摘要
相似文献
1
The heterogenous landscape of EGFR Del19 mutation subtype: not all are the same for osimertinib.表皮生长因子受体（EGFR）19号外显子缺失突变亚型的异质性情况：对于奥希替尼而言，并非所有情况都相同。
Transl Lung Cancer Res. 2024 Apr 29;13(4):952-955. doi: 10.21037/tlcr-24-30. Epub 2024 Apr 24.
2
CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation.CH7233163 克服奥希替尼耐药的 EGFR-Del19/T790M/C797S 突变。
Mol Cancer Ther. 2020 Nov;19(11):2288-2297. doi: 10.1158/1535-7163.MCT-20-0229. Epub 2020 Sep 17.
3
Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.非小细胞肺癌中表皮生长因子受体外显子 19 缺失、T790M 和 cis-C797S 三重突变患者对布加替尼靶向治疗的反应：一例报告。
Int J Mol Sci. 2022 Dec 29;24(1):602. doi: 10.3390/ijms24010602.
4
Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study.荷兰使用不同酪氨酸激酶抑制剂治疗晚期表皮生长因子受体突变非小细胞肺癌的总生存期：一项回顾性全国登记研究
Lancet Reg Health Eur. 2023 Feb 6;27:100592. doi: 10.1016/j.lanepe.2023.100592. eCollection 2023 Apr.
5
Sequential Afatinib and Osimertinib in Asian Patients with Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies.亚洲携带突变的非小细胞肺癌及获得性T790M患者序贯使用阿法替尼和奥希替尼：两项全球非干预性研究的联合分析
Onco Targets Ther. 2022 Aug 22;15:873-882. doi: 10.2147/OTT.S362535. eCollection 2022.
6
Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib.观察性研究：阿法替尼序贯奥希替尼治疗 EGFR 突变阳性 NSCLC：起始剂量为 40mg 的阿法替尼治疗患者。
Adv Ther. 2020 Feb;37(2):759-769. doi: 10.1007/s12325-019-01187-y. Epub 2019 Dec 20.
7
Landscape of Acquired Resistance to Osimertinib in -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired Fusion.奥希替尼获得性耐药的非小细胞肺癌的全景及奥希替尼联合 BLU-667 对获得性融合的 EGFR 和 RET 联合抑制的临床验证
Cancer Discov. 2018 Dec;8(12):1529-1539. doi: 10.1158/2159-8290.CD-18-1022. Epub 2018 Sep 26.
8
Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group.西班牙初治的表皮生长因子受体外显子19缺失（Del19 EGFR）非小细胞肺癌患者使用阿法替尼的真实世界数据：加利西亚肺癌组的临床经验
Cancer Treat Res Commun. 2022;33:100646. doi: 10.1016/j.ctarc.2022.100646. Epub 2022 Oct 4.
9
Sequential afatinib and osimertinib in patients with mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.奥希替尼序贯治疗表皮生长因子受体突变阳性非小细胞肺癌患者：观察性 GioTag 研究的更新分析。
Future Oncol. 2019 Sep;15(25):2905-2914. doi: 10.2217/fon-2019-0346. Epub 2019 Aug 2.
10
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG).表皮生长因子受体突变阳性非小细胞肺癌患者序贯阿法替尼和奥希替尼治疗：一项全球非干预性研究（UpSwinG）。
Lung Cancer. 2021 Dec;162:9-15. doi: 10.1016/j.lungcan.2021.09.009. Epub 2021 Sep 21.
本文引用的文献
1
Co-Occurring Alterations in Multiple Tumor Suppressor Genes Are Associated With Worse Outcomes in Patients With EGFR-Mutant Lung Cancer.多个肿瘤抑制基因的共发生改变与 EGFR 突变型肺癌患者的不良结局相关。
J Thorac Oncol. 2024 Feb;19(2):240-251. doi: 10.1016/j.jtho.2023.10.001. Epub 2023 Oct 6.
2
Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer.KRAS 突变型非小细胞肺癌的治疗策略
Cancers (Basel). 2023 Mar 7;15(6):1635. doi: 10.3390/cancers15061635.
3
Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations.奥希替尼治疗罕见 EGFR 外显子 19 缺失突变阳性肺癌患者的疗效。
Clin Cancer Res. 2023 Jun 1;29(11):2123-2130. doi: 10.1158/1078-0432.CCR-22-3497.
4
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.癌基因成瘾性转移性非小细胞肺癌：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2023 Apr;34(4):339-357. doi: 10.1016/j.annonc.2022.12.009. Epub 2023 Jan 23.
5
Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations.具有不同外显子 19 突变的 EGFR 对抑制剂敏感性差异的生化和结构基础。
Nat Commun. 2022 Nov 10;13(1):6791. doi: 10.1038/s41467-022-34398-z.
6
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.波齐替尼治疗 EGFR 外显子 20 突变型 NSCLC：临床疗效、耐药机制以及插入位置对药物敏感性的影响。
Cancer Cell. 2022 Jul 11;40(7):754-767.e6. doi: 10.1016/j.ccell.2022.06.006.
7
Structure-based classification predicts drug response in EGFR-mutant NSCLC.基于结构的分类预测 EGFR 突变型 NSCLC 的药物反应。
Nature. 2021 Sep;597(7878):732-737. doi: 10.1038/s41586-021-03898-1. Epub 2021 Sep 15.
8
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy.早期和局部晚期非小细胞肺癌：聚焦诊断、分期、全身及局部治疗的ESMO临床实践指南更新
Ann Oncol. 2021 Dec;32(12):1637-1642. doi: 10.1016/j.annonc.2021.08.1994. Epub 2021 Sep 1.
9
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.雷莫芦单抗联合厄洛替尼治疗 EGFR 外显子 19 缺失和外显子 21 L858R 突变的转移性非小细胞肺癌的 RELAY 亚组分析。
Clin Cancer Res. 2021 Oct 1;27(19):5258-5271. doi: 10.1158/1078-0432.CCR-21-0273.
10
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma.肺腺癌中 EGFR 外显子 19 突变 L747-A750>P 对酪氨酸激酶抑制剂表现出独特的敏感性。
Clin Cancer Res. 2019 Nov 1;25(21):6382-6391. doi: 10.1158/1078-0432.CCR-19-0780. Epub 2019 Jun 10.
Zotero 插件